Psychiatric Orders in Psychoanalytic Treatment of ASD
NCT05930912 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1
Last updated 2023-07-05
Summary
Autism Spectrum Disorder (ASD) is often accompanied by a variety of other symptoms, such as bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), Social Anxiety Disorder (SAD), Avoidant Personality Disorder (AvPD), Obsessive Compulsive Disorder (OCD), etc. The behavioral and social complications often marginalize the population, impact on life satisfaction, undermined societal values that impact on economic and financial fairness, and so forth. Furthermore, persons with ASD are neurodiverse from standardized pharmacological and clinical cares, and are interpreted disadvantaged in the context of neurotypical treatments.
The research protocol aims to differentiate the neuropharmacological implications of ASD from its behavioral and social implications. Such a differentiation is beneficial to the quality of care for neurodiverse population, both in terms of precision treatment in medical settings, and in terms of psychotherapeutic treatment efficacy in the interpretation of behavioral and social traits.
The study protocol continues from the adverse event of the participant in NCT05711810 trial, after the positive immunological results in the NCT05839236 trial. The intervention medicine continues from Sertraline adjusted on the choice of Selective Serotonin Reuptake Inhibitor (SSRI) in the previous two trials for complex post-traumatic stress disorder (CPTSD) of the participant, and its combined used with Duloxetine in the choice of Selective Norephedrine Reuptake Inhibitor (SNRI) for norephedrine regulations.
The hypothesized target is on the discrete psychiatric intervention centered approach to ASD treatment care. In the PRC where the study is being carried out, amphetamine class medicines are strictly prohibited and defined as illegal substances, regardless of their only proven effect for ASD patient care. Contributed by the sociostructural elements and necessities, black market amphetamine and ketamine have not only emerged in the regime for decades, but also have become a lucrative business. Their recreational uses are also sometimes accompanied by real necessities and needs; black markets cater to the needs but guidance on the usages is based on word-of-mouth stories without professional medical assistances. There is one case the Principal Investigator (PI) collected, that one person, possibly under depression contributed by PTSD, took relatively high dosage of amphetamine and went into a state of psychosis with overwhelming persecution mania. The study protocol, Psychiatric Orders in Psychoanalytic Treatment of ASD, is therefore designed for an evidence-based approach in treating complex psychiatric disorders with psychoanalytic guidance.
Conditions
- PTSD
- Autism Spectrum Disorder High-Functioning
- OCD
- Agoraphobia With Panic Attacks
- Depression, Unipolar
- Depression, Anxiety
- Depression and Suicide
- Depression, Reactive
- Depression; Psychoneurotic
- Depression Anxiety Disorder
- Panic Disorder With Agoraphobia, Severe Agoraphobic Avoidance and Mild Panic Attacks
- Anxiety Disorders
- ADHD - Combined Type
- Borderline Personality Disorder
- Social Anxiety Disorder
- Avoidant Personality Disorder
- Stockholm Syndrome
- Grief
- Separation Insecurity
Interventions
- DIAGNOSTIC_TEST
-
Psychoanalysis
Case-specific psychoanalysis is performed, including the participant's background during birth.
- DRUG
-
sertraline 50mg
After the initial assessment of 50 mg/d, the treatment dosage is determined at 100 mg/d.
- DRUG
-
Duloxetine 20 MG
Duloxetine is used with 20 mg/night for subsidiary effects with sertraline.
- BEHAVIORAL
-
Cognitive Behavioral Therapy
CBT is tailored to the participant's current activities and life decisions.
Sponsors & Collaborators
-
S for Science
collaborator UNKNOWN -
Yang I. Pachankis, PhD
lead INDIV
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-06-01
- Primary Completion
- 2023-09-01
- Completion
- 2023-12-01
- FDA Drug
- Yes
Countries
- China
Study Locations
More Related Trials
-
Assessing the Effectiveness of Psychiatric Interventions on the Inpatient Unit
NCT03626142 ·Status: ENROLLING_BY_INVITATION
-
Pharmacology of Cognition in Schizotypal Personality Disorder
NCT00353379 ·Status: TERMINATED ·Phase: PHASE4
-
The Optimal Treatment for Treatment-resistant Schizophrenia
NCT02926976 ·Status: UNKNOWN ·Phase: NA
-
Anti-psychotic Drug Prescribing Patterns Within Specialist Adult ID Services in England and Wales
NCT06238089 ·Status: RECRUITING
-
Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia
NCT00654576 ·Status: COMPLETED ·Phase: PHASE4
-
PSYCHIATRIC Disorders and Covid-19
NCT04358042 ·Status: TERMINATED
-
Efficacy and Safety of Psychopharmacotherapy in Patients With Schizophrenia or Bipolar Disorders
NCT00330226 ·Status: UNKNOWN
-
Side Effects of Psychiatric Medications - a Nested Case Control Cohort Historical Prospective Study
NCT05872555 ·Status: ACTIVE_NOT_RECRUITING
-
SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia
NCT04528095 ·Status: UNKNOWN ·Phase: PHASE3
-
Simvastatin Addition for Patients With Recent-onset Schizophrenia
NCT01999309 ·Status: COMPLETED ·Phase: PHASE3
-
RCT of Methotrexate Added to Treatment As Usual in Schizophrenia
NCT02074319 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Sertindole on Sensory Gating and Cognition in Healthy Volunteers
NCT00612079 ·Status: COMPLETED ·Phase: NA
-
A Study of an Cognitive Behaviour Therapy for Internalised Stigma Intervention for Inpatients With Psychosis
NCT02853396 ·Status: UNKNOWN ·Phase: NA
-
Study on Predictiors and Mechanism of Conversion to Psychosis in Individuals at Ultra-high Risk Group
NCT03965598 ·Status: UNKNOWN
-
Inpatient Group Acceptance and Commitment Therapy (ACT) for Psychosis Spectrum Disorder
NCT06086184 ·Status: RECRUITING ·Phase: NA
-
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05958875 ·Status: RECRUITING ·Phase: PHASE4
-
Enhancing Educational and Vocational Recovery in Adolescents and Young Adults With Early Psychosis Through Supported Employment and Education.
NCT05824117 ·Status: UNKNOWN ·Phase: NA
-
Effectiveness of Anti-Psychotic in GPs Setting
NCT00543088 ·Status: COMPLETED
-
Young Adults With Violent Behavior During Early Psychosis (Aim 2)
NCT05756855 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Cognitive Therapy for Negative Symptoms and Functioning
NCT00350883 ·Status: COMPLETED ·Phase: PHASE2
-
Acceptance and Commitment Therapy (ACT) in Early Psychosis Patients
NCT05210816 ·Status: COMPLETED ·Phase: NA
-
Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis
NCT00465920 ·Status: UNKNOWN ·Phase: PHASE2
-
Developing Dual-channel Transcranial Alternating Current Stimulations Targeting Negative Symptoms in Schizophrenia
NCT04859504 ·Status: COMPLETED ·Phase: NA
-
Trial and Follow-up of the Efficacy of Two-stage Integrated Treatment for Chinese Schizophrenia Inpatients
NCT02850445 ·Status: UNKNOWN ·Phase: NA
-
Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
NCT03649581 ·Status: RECRUITING ·Phase: NA